Latest Breaking News On - Cebile capital - Page 1 : comparemela.com

For most companies, making a product for which theres guaranteed demand Around The World sounds too good to be true, but a successful covid 19 vaccine promises to be just that. One vaccine shot, or a couple as your first booster, is not going to provide lifetime immunity to the virus, so the manufacturers are set to reap the profits for years to come. Drug maker pfizer reports its earnings later today, the question is which of the drugs firms are going to come out on top, and how lucrative Will Making Vaccines actually turn out to be . Joining me now is Sunaina Sinha haldea, managing partner, cebile capital. Thank you for being on the program. First of all, pfizer, when it comes to its news today. This will obviously not have in todays earnings, profits it is going to make with this vaccine it has come up with this vaccine it has come up with biontech . M0 with this vaccine it has come up with biontech . With this vaccine it has come up with biontech . No it wont. There will up with bi

Bbc newsThe business of making vcaccinesAround the worldAccellerating trendCovid 19Drug maker pfizerWill making vaccinesDrugs firmsVaccine shotSunaina sinha haldeaManaging partnerCebile capitalWon tRevenue upRevenue bumpLong term